Investors are increasingly wary of the rare-disease space, spooked by a regulatory shift.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines
Investors are increasingly wary of the rare-disease space, spooked by a regulatory shift.